AstraZeneca set to showcase the latest in respiratory science at the 2018 European Respiratory Society (ERS) International Congress
At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines, along with scientific research targeting the underlying causes of the diseases. We look forward to joining clinicians, researchers and scientists at the 2018 European Respiratory Society (ERS) International Congress to share the latest in respiratory science advancements. Follow us on Twitter and LinkedIn, and join the conversation using #ERSCongress.
Severe asthma is a debilitating, life-threatening disease that affects as many as an estimated 33 million people worldwide. Our experts shared their thoughts in a recent article in The Economist outlining how this disease continues to be misunderstood and how AstraZeneca is following the science to harness the great potential to improve treatment and outcomes.
Targeting the inaccessible: new drug modalities in lung disease
Anticalin® molecules are small engineered proteins mimicking monoclonal antibodies but with the advantage of direct delivery to the lung.
Targeting epithelial cytokines may prevent the release of pro-inflammatory cytokines by immune cells, which may result in the prevention of asthma exacerbations and improved asthma control.
Immunostimulatory oligonucleotides have the potential to correct imbalances in the immune system that are seen in many asthma sufferers.
Our aim is to modify and ultimately cure Respiratory disease. To get there, we need to be able to target any novel biology we uncover and address targets previously seen as inaccessible. This is where new, inhaled drug modalities will help us succeed.
Supporting changes in respiratory clinical care
Pushing the boundaries to deliver innovative solutions
AstraZeneca has taken the number one spot in IDEA Pharma’s Pharmaceutical Innovation Index – celebrating the most innovative companies in pharma. Hear more from the people who are leading in respiratory.
Vice President and Head, RIA Innovative Medicines
Therapy Area Vice President, Respiratory
Rene Van der Merwe
Vice President, Clinical Respiratory
Head, Respiratory Global Medicines, AstraZeneca and CEO of Pearl Therapeutics
Veeva ID: Z4-12475
Date of next review:
At AstraZeneca Respiratory, we’re driven by innovation and our commitment to make a real life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2017 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.